In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nestlé Gets Serious With Seres Deal

Executive Summary

The January Nestlé Health-Seres alliance nets Seres one of the biggest up-front payments in several years for an ex-US product license, while Nestlé shows its continuing commitment to building a portfolio of GI nutritional therapeutics – an area where development efforts have been slow to take shape.

You may also be interested in...



Microbiotica: Wellcome Spin-Out Exploits Unique Microbe Collection

Emerging Company Profile: Microbiotica, a UK biotech spin-out from the Wellcome Trust Sanger Institute announced late last year, says it has unique capabilities in culturing and sequencing the human bacterial microbiome that will be of use to develop bacterial mixes for therapeutic use.

Start-Up Quarterly Statistics, Q1 2016

Start-ups raised $1.8 billion in Q1 2016. Biopharma companies penned 33 alliances; 14 acquisitions were signed (11 in the biopharma industry).

Eyeing Multiple Development Paths, Pronutria Takes $12.5 Million Series B

The Cambridge, Mass.-based developer of medical foods and supplements has begun clinical trials on two candidates to stave off muscle loss in elderly people. It soon may begin development of therapeutic product candidates within a separate business unit.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel